BioMarin Pharmaceuticalvs.Moderna
BMRN vs MRNA · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Moderna is about 1.9× larger than BioMarin Pharmaceutical by market cap; year to date, Moderna leads (+371.0% vs +9.5%).
Side by side
| BMRN | MRNA | |
|---|---|---|
| Market cap | $13.4B | $25.2B |
| Price | $66.12 | $158.83 |
| Today | +1.6% | +14.4% |
| Return YTD | +9.5% | +371.0% |
| Return 1Y | +11.1% | +412.1% |
| P/E | 183.0 | — |
| P/S | 3.9 | 11.3 |
| P/B | 2.1 | 3.7 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
BioMarin PharmaceuticalBMRN
Rare genetic disorders define the company. It sells enzyme replacement therapies and Voxzogo for dwarfism, and has taken gene therapy into hemophilia.
Full BMRN profile →ModernaMRNA
Built on mRNA, the technology behind its covid vaccine. The pipeline pushes the same platform into further vaccines and into oncology.
Full MRNA profile →More BMRN & MRNA comparisons
Other head-to-heads in the Biotech & innovation segment.
See where BMRN and MRNA sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →